BTOG wishes to inform members of a new NICE release that has been published today.
NICE has recommended Lorlatinib as an option for ALK-positive advanced non-small-cell lung cancer in adults who have not had an ALK inhibitor.
There is a commercial access agreement for Lorlatinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal.
For full details and the documents, please see the NICE website:
BTOG wishes to inform members of a new NICE release that has been published today. Following review of the original technical appraisal, NICE no longer recommend sotorasib for treating KRAS G12C mutation-positive locally advanced or metastatic non-small-cell...
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended serplulimab with carboplatin and etoposide within its marketing authorisation, as an option for untreated extensive-stage small cell lung cancer in adults....
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended cemiplimab with platinum-based chemotherapy - it can be used as an option for untreated non-small-cell lung cancer (NSCLC) in adults: if they would otherwise...
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended amivantamab with carboplatin and pemetrexed during the managed access period as an option for untreated advanced non-small-cell lung cancer (NSCLC) with...
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended osimertinib, within its marketing authorisation, as an option to treat unresectable locally advanced (stage 3) non-small-cell lung cancer (NSCLC) in adults....
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended encorafenib plus binimetinib as an option to treat BRAF V600E mutation-positive advanced non-small-cell lung cancer (NSCLC) in adults, only if it is used at...
BTOG wishes to inform members of a new NICE release that has been published today for nivolumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. NICE has recommended nivolumab...
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended amivantamab plus lazertinib, within its marketing authorisation, as an option for untreated advanced non-small-cell lung cancer (NSCLC) in adults whose tumours have...
BTOG wishes to inform members of a new NICE release that has been published today.NICE has recommended Durvalumab, within its marketing authorisation, as an option to treat limited-stage small-cell lung cancer that has not progressed after platinum-based...
BTOG can confirm that NICE has released draft guidance as follows: Osimertinib should not be used for the maintenance treatment of locally advanced (stage 3) unresectable non-small cell lung cancer (NSCLC) in adults when the tumours have epidermal growth factor...